BioSpace News Archive

Moderna, Inc. today announced the first participant has been dosed in the Phase 2/3 study of mRNA-1345, the Company’s Respiratory Syncytial Virus (RSV) vaccine candidate.

Altay Therapeutics, RADD Pharmaceuticals, Rubik Therapeutics, VastBiome and Waypoint Bio to receive free year of lab bench use and other amenities at prominent bioscience incubators.

Avilar Therapeutics today announced a $60 million seed financing from founding investor RA Capital Management.

Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that Gilead has exercised its options to three programs in Arcus’s clinical-stage portfolio, including both anti-TIGIT molecules, domvanalimab and AB308, as well as etrumadenant and quemliclustat.

Lassen Therapeutics today announced the appointment of Puneet S. Arora, M.D. as Chief Medical Officer.

Sanofi announced an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.

The vendor landscape of the global non-small cell lung cancer therapeutics market features the presence of a number of players, but was dominated by Genentech, a Roche company, which accounted for nearly 36% of the overall market in 2014, observes a recent report by Transparency Market Research.

Iron-deficiency anemia is a common type of anemia when the body does not have enough iron.

Medivir AB announces that results from the investigator-initiated phase II clinical study in patients with squamous cell carcinoma has been published in JAMA Dermatology by Kilgour, JM et al.

Generate Biomedicines, whose machine learning-powered Generative Biology platform can rapidly invent new drugs across a wide range of protein modalities and previously undiscoverable protein therapeutics, announced it has raised $370 Million in a Series B financing to advance the development of its novel drug generation platform.